DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully

Sara E Meyer1, Tingting Qin2, David E Muench1

  • 1Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Cancer Discovery
|March 27, 2016
PubMed
Abstract

Insights

DNMT3A haploinsufficiency combined with FLT3 mutations drives acute myeloid leukemia (AML) development. This transformation involves epigenetic changes that are reversible, offering potential therapeutic strategies for AML.

Area of Science:

  • Hematology
  • Cancer Biology
  • Epigenetics

Background:

  • Cytogenetically normal acute myeloid leukemia (CN-AML) accounts for nearly 50% of human AML cases.
  • Co-occurring mutations in DNMT3A and FLT3 are prevalent in CN-AML and associated with poor prognosis.

Purpose of the Study:

  • To investigate the role of DNMT3A haploinsufficiency in the development of FLT3-mutant AML.
  • To explore the reversibility of epigenetic alterations and their impact on AML clonogenicity.

Main Methods:

  • Development of a murine model with inducible Dnmt3a deletion and Flt3-internal tandem duplication (Flt3(ITD)).
  • Analysis of DNA methylation patterns and gene expression in primary and murine AML.
  • Utilized single-cell assays, including single-cell RNA sequencing, to dissect cellular architecture.

Main Results:

  • Mice with Flt3(ITD) and Dnmt3a deletion developed a rapidly lethal, transplantable AML.
  • DNMT3A haploinsufficiency was sufficient to drive AML development, and its effects were reversible upon restoring expression.
  • Identified clonogenic AML subpopulations sensitive to DNMT3A levels and methylation changes.

Conclusions:

  • DNMT3A haploinsufficiency transforms FLT3(ITD)-mutant myeloproliferative neoplasms into AML through reversible epigenetic alterations.
  • Modulation of methylation-sensitive gene expression in specific subpopulations is key to DNMT3A's oncogenic effects.
  • The reversibility of DNMT3A-mutant AML suggests potential therapeutic avenues.

Related Concept Videos

Translation01:31

Translation

Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
21.8K
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
159.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66